This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Mouse model of early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with IL-7 receptor (CD127) mutation	<p>A mouse model of ETP-ALL could help identify new therapeutics for the disease. In immature thymocytes, expression of a mutant form of CD127 found in pediatric cases of ETP-ALL blocked differentiation of thymocytes early in development. In irradiated mice, transplantation of thymocytes expressing mutant Cd127, but not wild-type Cd127, caused lethal leukemia with similar gene expression patterns as the human pediatric cancers. In the ETP-ALL mouse model, the Janus kinase-1 (JAK-1) and JAK-2 inhibitor Jakafi ruxolitinib increased survival compared with vehicle. Next steps could include using the model to identify other therapeutics for ETP-ALL.</p> <p>Incyte Corp. and Novartis AG market Jakafi to treat myeloproliferative disorder.</p> <p>SciBX 7(18); doi:10.1038/scibx.2014.539 Published online May 8, 2014</p>	Patent and licensing status unavailable	<p>Treanor, L.M. <i>et al. J. Exp. Med.</i>; published online March 31, 2014; doi:10.1084/jem.20122727</p> <p>Contact: Brian P. Sorrentino, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: brian.sorrentino@stjude.org</p>